ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reached 31.04% versus a 1-year low price of $20.68. The stock was last seen 3.12% higher, reaching at $27.1 on Jun. 16, 2017. At recent session, the prices were hovering between $26.16 and $27.2. This company shares are 63.1% off its target price of $44.2 and the current market capitalization stands at $3.21B. The recent change has given its price a -9.54% deficit over SMA 50 and -33.63% deficit over its 52-week high. The stock witnessed 0.15% gains, -27.01% declines and 8.66% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ACAD’s volatility during a week at 3.66% and during a month it has been found around 3.71%.

ACADIA Pharmaceuticals Inc. (ACAD) Top Holders

Institutional investors currently hold around $3.26 billion or 99.2% in ACAD stock. Look at its top three institutional owners. Baker Bros. Advisors Lp owns $699.72 million in ACADIA Pharmaceuticals Inc., which represents roughly 21.8% of the company’s market cap and approximately 21.48% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 18,211,143 shares of the stock are valued at $493.52 million. The third largest holder is Vanguard Group Inc, which currently holds $202.43 million worth of this stock and that ownership represents nearly 6.31% of its market capitalization.

ACADIA Pharmaceuticals Inc. 13F Filings

At the end of Mar reporting period, 124 institutional holders increased their position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by some 9,641,469 shares, 103 decreased positions by 10,291,742 and 29 held positions by 100,243,264. That puts total institutional holdings at 120,176,475 shares, according to SEC filings. The stock grabbed 39 new institutional investments totaling 3,760,452 shares while 33 institutional investors sold out their entire positions totaling 2,705,580 shares.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Trades

Multiple company employees have indulged in significant insider trading. ACADIA Pharmaceuticals Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP, CHIEF COMMERCIAL OFFICER Moore Terrence O has sold 7,856 shares of ACADIA Pharmaceuticals Inc. (ACAD) in trading session dated Feb. 21, 2017. These shares are worth $311,490 and were traded at $39.65 each. The SEC filing shows that Moore Terrence O performed a sale of 157,540 shares. The EVP, CHIEF COMMERCIAL OFFICER disposed these shares by way of transaction on Feb. 16, 2017. The company’s shares were given away at $39.77 per share worth to an income of some $6,265,366 on account of Moore Terrence O.

EVP AND GC, Baity Glenn, sold 26,365 common shares of ACADIA Pharmaceuticals Inc. (ACAD) in the open market. In a transaction dated Feb. 14, 2017, the shares were put up for sale at an average price of $39.66, raking in a sum of $1,045,636. After this sale, 67,063 common shares of ACAD are directly owned by the insider, with total stake valued at $1,817,407.

In the transaction dated Feb. 01, 2017, the great number of shares disposed came courtesy the EVP AND GC; Baity Glenn disposed a total of 31,078 shares at an average price of $35.15, amounting to approximately $1,092,392. The insider now directly owns 67,063 shares worth $1,817,407.

ACADIA Pharmaceuticals Inc. (ACAD) Analyst Guide

Several analysts have released their opinion on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), with 7 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.6 average brokerage recommendation.

Previous articleGlobalstar, Inc. (GSAT) loses confidence of 21 hedge fund managers
Next article47 hedge funds buy Bioverativ Inc. (BIVV) for the first time